---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-118338"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:35:16.113825+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TriSalus Q3 revenue up 42% to $7.3M; guides for 50%+ growth and positive EBITDA in 2025

## Summary
- Q3 revenue $7.3M (+42% YoY); nine-month revenue $21.2M (+66% YoY). Gross margin 86%.
- Operating loss improved to $8.7M (Q3) and $28.6M (9M) from $18.6M and $40.2M in 2023.
- Net loss per share $0.12 (Q3) vs $0.14; cash $11.3M plus $25M OrbiMed facility.
- 2025 guidance: >50% revenue growth, >20% opex reduction, positive full-year EBITDA, H2 cash flow positive.
- Launched TriNav LV system and TriGuide catheter; initiated PROTECT trial for thyroid embolization ($400M market).

## SEC filing metadata
- accession: 0001104659-24-118338
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465924118338/0001104659-24-118338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465924118338/tm2428379d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-118338
- JSON: https://secwatch.observer/filing/0001104659-24-118338.json
- Plain text: https://secwatch.observer/filing/0001104659-24-118338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.